Logo image of 2X1.DE

ABIVAX SA (2X1.DE) Stock Fundamental Analysis

Europe - FRA:2X1 - FR0012333284 - Common Stock

70.2 EUR
+0.6 (+0.86%)
Last: 9/18/2025, 7:00:00 PM
Fundamental Rating

2

Taking everything into account, 2X1 scores 2 out of 10 in our fundamental rating. 2X1 was compared to 75 industry peers in the Biotechnology industry. Both the profitability and financial health of 2X1 have multiple concerns. 2X1 has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

2X1 had negative earnings in the past year.
2X1 had negative earnings in each of the past 5 years.
In the past 5 years 2X1 always reported negative operating cash flow.
2X1.DE Yearly Net Income VS EBIT VS OCF VS FCF2X1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

With a Return On Assets value of -105.57%, 2X1 is not doing good in the industry: 76.00% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -105.57%
ROE N/A
ROIC N/A
ROA(3y)-74.48%
ROA(5y)-62.72%
ROE(3y)-493.52%
ROE(5y)-485.85%
ROIC(3y)N/A
ROIC(5y)N/A
2X1.DE Yearly ROA, ROE, ROIC2X1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

1.3 Margins

2X1 does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2X1.DE Yearly Profit, Operating, Gross Margins2X1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

3

2. Health

2.1 Basic Checks

Compared to 1 year ago, 2X1 has more shares outstanding
2X1 has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, 2X1 has a worse debt to assets ratio.
2X1.DE Yearly Shares Outstanding2X1.DE Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
2X1.DE Yearly Total Debt VS Total Assets2X1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

2X1 has an Altman-Z score of 11.04. This indicates that 2X1 is financially healthy and has little risk of bankruptcy at the moment.
2X1 has a better Altman-Z score (11.04) than 86.67% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z 11.04
ROIC/WACCN/A
WACCN/A
2X1.DE Yearly LT Debt VS Equity VS FCF2X1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M

2.3 Liquidity

2X1 has a Current Ratio of 1.25. This is a normal value and indicates that 2X1 is financially healthy and should not expect problems in meeting its short term obligations.
2X1 has a Current ratio of 1.25. This is in the lower half of the industry: 2X1 underperforms 69.33% of its industry peers.
A Quick Ratio of 1.25 indicates that 2X1 should not have too much problems paying its short term obligations.
2X1 has a worse Quick ratio (1.25) than 65.33% of its industry peers.
Industry RankSector Rank
Current Ratio 1.25
Quick Ratio 1.25
2X1.DE Yearly Current Assets VS Current Liabilites2X1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

2X1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 18.52%, which is quite good.
EPS 1Y (TTM)18.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, 2X1 will show a decrease in Earnings Per Share. The EPS will decrease by -1.36% on average per year.
Based on estimates for the next years, 2X1 will show a very strong growth in Revenue. The Revenue will grow by 154.04% on average per year.
EPS Next Y3.43%
EPS Next 2Y26.23%
EPS Next 3Y-1.36%
EPS Next 5YN/A
Revenue Next Year124.58%
Revenue Next 2Y19.15%
Revenue Next 3Y226.97%
Revenue Next 5Y154.04%

3.3 Evolution

2X1.DE Yearly Revenue VS Estimates2X1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
2X1.DE Yearly EPS VS Estimates2X1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 1 -1 -2 -3

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for 2X1. In the last year negative earnings were reported.
Also next year 2X1 is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
2X1.DE Price Earnings VS Forward Price Earnings2X1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
2X1.DE Per share data2X1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5 -2 -2.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y26.23%
EPS Next 3Y-1.36%

More info and screens

0

5. Dividend

5.1 Amount

2X1 does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ABIVAX SA

FRA:2X1 (9/18/2025, 7:00:00 PM)

70.2

+0.6 (+0.86%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-08 2025-09-08/amc
Earnings (Next)12-15 2025-12-15
Inst Owners42.26%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap5.31B
Analysts87.69
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.8
EYN/A
EPS(NY)-1.08
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS-0.09
TBVpS-0.42
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -105.57%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-74.48%
ROA(5y)-62.72%
ROE(3y)-493.52%
ROE(5y)-485.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.25
Quick Ratio 1.25
Altman-Z 11.04
F-ScoreN/A
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)54.18%
Cap/Depr(5y)310.65%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.52%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y3.43%
EPS Next 2Y26.23%
EPS Next 3Y-1.36%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year124.58%
Revenue Next 2Y19.15%
Revenue Next 3Y226.97%
Revenue Next 5Y154.04%
EBIT growth 1Y-35.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year6.9%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-58.85%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-58.62%
OCF growth 3YN/A
OCF growth 5YN/A